Compare ERC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | ZNTL |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.9M | 289.0M |
| IPO Year | N/A | 2020 |
| Metric | ERC | ZNTL |
|---|---|---|
| Price | $8.98 | $3.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 93.9K | ★ 975.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.72 | $1.13 |
| 52 Week High | $9.78 | $6.95 |
| Indicator | ERC | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 45.43 |
| Support Level | $8.90 | $3.44 |
| Resistance Level | $9.23 | $4.38 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 30.94 | 35.46 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.